Market Newsdesk

OKLAHOMA CITY
, Aug. 4, 2025 /PRNewswire/ — SandRidge Energy, Inc. (the “Company” or “SandRidge”) (NYSE: SD) today announced plans to release second quarter 2025 operational and financial results after the close of trading on Wednesday, August 6, 2025.

SandRidge will host a conference call on Thursday, August 7, 2025 at 1:00 p.m. Central Time to review second quarter 2025 financial results and operational highlights.  The conference call can be accessed by registering online in advance at https://registrations.events/direct/Q4I231503.6267774588438875e+24 at which time registrants will receive dial-in information as well as a conference ID. At the time of the call, participants will dial in using the participant number and conference ID provided upon registration.

A live audio webcast of the conference call will also be available via the Company’s website, investors.sandridgeenergy.com, under Investor Relations/Presentation & Events. The webcast will be archived for replay on the Company’s website for at least 30 days.

About SandRidge Energy, Inc.

SandRidge Energy, Inc. (NYSE: SD) is an independent oil and gas company engaged in the production, development, and and acquisition of oil and gas properties. Its primary area of operations is is the Mid-Continent  region in Oklahoma, Texas, and Kansas.  Further information can be found at sandridgeenergy.com.

Contact Information

Investor Relations
SandRidge Energy, Inc.
1 E. Sheridan Ave. Suite 500
Oklahoma City, OK 73104
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/sandridge-energy-inc-announces-second-quarter-2025-operational-and-financial-results-release-date-and-conference-call-information-302520186.html

SOURCE SANDRIDGE ENERGY, INC.

HOUSTON
, Aug. 4, 2025 /PRNewswire/ — Direct Digital Holdings, Inc. (Nasdaq: DRCT) (“Direct Digital Holdings” or the “Company”), a leading advertising and marketing technology platform operating through its companies Colossus Media, LLC (“Colossus SSP”) and Orange 142, LLC (“Orange 142”), today announced that the Company will report financial results for the second quarter ended June 30, 2025 on Tuesday, August 5, 2025 after the U.S. stock market closes.

Management will host a conference call and webcast on the same day at 5:00 PM ET to discuss the results. The live webcast and replay can be accessed at https://ir.directdigitalholdings.com/news-events/ir-calendar.

About Direct Digital Holdings
Direct Digital Holdings (Nasdaq: DRCT) combines cutting-edge sell-side and buy-side advertising solutions, providing data-driven digital media strategies that enhance reach and performance for brands, agencies, and publishers of all sizes. Our sell-side platform, Colossus SSP, offers curated access to premium, growth-oriented media properties throughout the digital ecosystem. On the buy-side, Orange 142 delivers customized, audience-focused digital marketing and advertising solutions that enable mid-market and enterprise companies to achieve measurable results across a range of platforms, including programmatic, search, social, CTV, and influencer marketing. With extensive expertise in high-growth sectors such as Energy, Healthcare, Travel & Tourism, and Financial Services, our teams deliver performance strategies that connect brands with their ideal audiences.

At Direct Digital Holdings, we prioritize personal relationships by humanizing technology, ensuring each client receives dedicated support and tailored digital marketing solutions regardless of company size. This empowers everyone to thrive by generating billions of monthly impressions across display, CTV, in-app, and emerging media channels through advanced targeting, comprehensive data insights, and cross-platform activation. DDH is “Digital advertising built for everyone.”

Contacts:

Investors:
IMS Investor Relations
Walter Frank/Jennifer Belodeau
(203) 972-9200
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/direct-digital-holdings-to-report-second-quarter-2025-financial-results-302520249.html

SOURCE Direct Digital Holdings

PITTSBURGH
, Aug. 4, 2025 /PRNewswire/ — The Board of Directors of MSA Safety Incorporated (NYSE: MSA) today declared a third quarter dividend of $0.53 per share on common stock, payable September 10, 2025, to shareholders of record on August 15, 2025.

The Board also declared a dividend of $0.5625 per share on preferred stock, payable September 1, 2025, to shareholders of record on August 15, 2025.

About MSA Safety

MSA Safety Incorporated (NYSE: MSA) is the global leader in advanced safety products, technologies and solutions. Driven by its singular mission of safety, the company has been at the forefront of safety innovation since 1914, protecting workers and facility infrastructure around the world across a broad range of diverse end markets while creating sustainable value for shareholders. With 2024 revenues of $1.8 billion, MSA Safety is headquartered in Cranberry Township, Pennsylvania and employs a team of over 5,000 associates across its more than 40 international locations. For more information, please visit

www.MSASafety.com

.

View original content to download multimedia:https://www.prnewswire.com/news-releases/msa-safety-declares-quarterly-dividend-302520148.html

SOURCE MSA Safety

NATICK, Mass.
, Aug. 4, 2025 /PRNewswire/ — Cognex Corporation (NASDAQ: CGNX), the global technology leader in industrial machine vision, today announced that Dennis Fehr, Chief Financial Officer, will participate in a fireside chat at the KeyBanc Capital Markets Technology Leadership Forum on Monday, August 11, at 1:30 p.m. Mountain Time.

The live webcast and subsequent replay can be accessed from Cognex’s Investor Relations website at www.cognex.com/investor.

About Cognex Corporation 

For over 40 years, Cognex has been making advanced machine vision easy, paving the way for manufacturing and distribution companies to become faster, smarter, and more efficient through automation. Innovative technology in our vision sensors and systems solves critical manufacturing and distribution challenges, providing unparalleled performance for industries from automotive to consumer electronics to packaged goods.

Cognex makes these tools more capable and easier to deploy thanks to a longstanding focus on AI, helping factories and warehouses improve quality and maximize efficiency without needing highly technical expertise. We are headquartered near Boston, USA, with locations in over 30 countries and more than 30,000 customers worldwide. Learn more at cognex.com.

Investor Contacts:

Greer Aviv – Head of Investor Relations
Jordan Bertier – Senior Manager, Investor Relations
Cognex Corporation
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/cognex-to-present-at-the-keybanc-capital-markets-technology-leadership-forum-302520145.html

SOURCE Cognex Corporation

NetworkNewsWire Editorial Coverage

NEW YORK
, Aug. 4, 2025 /PRNewswire/ — As America’s population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trump administration’s “Make America Healthy Again” initiatives have emphasized improving access to treatments and accelerating medical innovation. Advancing this mission, Soligenix Inc. (NASDAQ: SNGX) (Profile) is making strides with its HyBryte(TM) platform, a novel therapy aimed at treating cutaneous T-cell lymphoma (CTCL), a rare skin cancer that primarily affects older adults. With successful U.S.-based manufacturing of HyBryte’s active ingredient now in place, Soligenix exemplifies the kind of domestic innovation poised to make a meaningful impact on this underserved patient population. The company is one of several impressive companies committed to making an impact in the pharmaceutical space, including Pfizer Inc. (NYSE: PFE), Merck & Co Inc. (NYSE: MRK), Bristol-Myers Squibb Co. (NYSE: BMY) and Insmed Inc. (NASDAQ: INSM).

• Soligenix Inc.’s HyBryte platform represents a promising therapeutic option for cutaneous T-cell lymphoma, a rare cancer that often affects older adults.
• A second confirmatory phase 3 clinical trial for HyBryte is underway and represents a pivotal step in advancing the therapy toward global commercialization for the treatment of early-stage CTCL.
• HyBryte received both U.S. and EU orphan drug designations as well as Fast Track status from the FDA, underscoring the serious unmet medical need it addresses.
• A critical attribute of HyBryte in the treatment of CTCL is its consistently strong safety profile, demonstrated across multiple clinical studies.

Click here to view the custom infographic of the Soligenix Inc. editorial.

Chronic rare diseases are emerging as a major challenge within the aging U.S. population. As life expectancy increases, so too does the complexity of healthcare needs, particularly when it comes to conditions that are both long-lasting and difficult to diagnose. Tens of millions of Americans are facing life with a rare disease, and many of them are seniors whose symptoms can easily be dismissed as normal signs of aging.

Because rare diseases often present subtly or mimic more common age-related issues, diagnosis in older adults can be delayed by years, hindering access to effective care and worsening outcomes. Compounding the issue is the limited availability of FDA-approved treatments. With thousands of rare diseases identified, the vast majority remain without approved therapies, underscoring the importance of continued investment in research and development. Seniors, in particular, are vulnerable to underdiagnosis and undertreatment, especially when the healthcare system is not attuned to the nuanced presentation of rare conditions in older adults.

In response, the “Make America Healthy Again” initiative has spotlighted the growing burden of chronic and rare diseases. Through targeted policies aimed at accelerating research, improving diagnostic tools and expanding access to care, these efforts seek to address the needs of older Americans grappling with complex, often overlooked, health challenges.

Companies such as Soligenix Inc. are rising to meet this need. The firm’s HyBryte program represents a promising therapeutic option for cutaneous T-cell lymphoma, a rare cancer that often affects older adults. Soligenix has recently completed the successful U.S. manufacturing transfer of HyBryte’s active ingredient, advancing its mission to bring effective, innovative treatments to patients most in need.

Cutaneous T-cell lymphoma (CTCL) is a rare form of non-Hodgkin’s lymphoma (NHL) that primarily affects the skin. Unlike other lymphomas, CTCL involves malignant T-cells that migrate to the skin’s surface, forming patches, lesions or tumors. This chronic cancer most commonly appears in older adults, making it particularly relevant to the aging population. Despite its rarity, CTCL remains a serious medical concern, affecting more than 40,000 NHL patients globally.

There is currently no known cure for CTCL, and treatment is often limited to managing symptoms and slowing disease progression. The most prevalent subtype of CTCL is mycosis fungoides (MF), which accounts for approximately 90% of all CTCL cases. In its early stages (I–IIA), MF has a relatively high five-year survival rate of 88%, but it remains a lifelong illness. As a chronic condition with no approved first-line therapy for early-stage patients, CTCL represents a clear unmet medical need.

The global market opportunity for CTCL therapies in the seven major markets (the United States, EU4, the United Kingdom and Japan) was estimated at about $995 million in 2024, with the U.S. accounting for some 70% of that. In addition, DelveInsight notes that “the expected launch of therapies such as HyBryte . . . will also boost the CTCL market growth.” Without these new therapies, effective treatment options remain limited, especially for those diagnosed in the early stages. Many patients undergo a series of therapies with limited success, underscoring the need for innovative, targeted treatments.

Soligenix’s HyBryte (synthetic hypericin) offers a promising solution as a potential first-line therapy for early-stage CTCL. By addressing this critical gap in care, HyBryte has the potential to significantly improve quality of life for thousands of patients and become a leading treatment option in this underserved market.

Soligenix’s second confirmatory phase 3 clinical trial for HyBryte, known as FLASH2, is currently underway and represents a pivotal step in advancing the therapy toward global commercialization for the treatment of early-stage CTCL. Designed to reinforce the positive findings of the initial FLASH study, FLASH2 has been accepted by the European Medicines Agency (EMA), while discussions with the U.S. Food and Drug Administration (FDA) remain ongoing.

This validation by European regulators underscores the robustness of the trial design and its alignment with international standards for therapeutic approval. The FLASH2 study maintains a similar structure to its predecessor but features an extended double-blind, placebo-controlled treatment duration of 18 weeks, three times longer than the original six-week period in the first FLASH trial. This longer timeline is expected to provide even more comprehensive data on HyBryte’s safety and efficacy. Importantly, key elements such as the patient inclusion and exclusion criteria and the primary endpoint remain consistent between the two studies, supporting the integrity and comparability of the trial outcomes.

Approximately 80 patients will be enrolled across clinical sites in both the United States and Europe. This multinational approach is intended to support broad regulatory submissions and pave the way for HyBryte’s commercial launch on a global scale. With enrollment progressing on schedule, Soligenix anticipates reporting top-line results in 2026, data that could significantly bolster the case for HyBryte as the first approved front-line treatment for early-stage CTCL.

As Soligenix continues to advance this promising therapy, FLASH2 stands as a potentially transformational milestone in the company’s effort to address a long-standing unmet medical need within the rare disease and oncology communities.

Soligenix’s HyBryte achieved positive, statistically significant results in its first phase 3 clinical trial, known as the FLASH study, marking a critical advancement in the treatment of early-stage CTCL. HyBryte received both U.S. and EU orphan drug designations as well as Fast Track status from the FDA, underscoring the serious unmet medical need it addresses.

Unlike many CTCL therapies that require a year or more to demonstrate efficacy, HyBryte showed a statistically significant treatment response in just six weeks, with response rates improving to 40% at 12 weeks and 49% at 18 weeks. The therapy demonstrated effectiveness across both patch and deeper plaque lesions, an important distinction given that many current early-stage CTCL treatments are primarily effective only on patch-type manifestations. This broader lesion response highlights HyBryte’s unique therapeutic potential within a complex and varied disease presentation. The study’s design and outcomes also reflect the treatment’s clinical promise as a practical, noninvasive solution that could change the standard of care for CTCL patients.

Safety and tolerability further set HyBryte apart. The FLASH trial reported minimal adverse events, a significant benefit when compared to other CTCL therapies that are often associated with both acute and chronic side effects. This favorable safety profile may make HyBryte especially appealing to older patients who are frequently managing multiple health conditions.

Additionally, HyBryte’s use of visible fluorescent light rather than ultraviolet (UV) light avoids the carcinogenic risks typically associated with conventional phototherapy. This novel light-based activation of synthetic hypericin enhances patient safety while maintaining therapeutic efficacy. Collectively, the FLASH and FLASH2 study results position HyBryte as a strong candidate to become the first approved front-line treatment for early-stage CTCL, offering a faster, safer, and more effective alternative to existing therapies.

A critical attribute of HyBryte in the treatment of CTCL is its consistently strong safety profile, demonstrated across multiple clinical studies. Unlike many current therapies for early-stage CTCL, which are typically associated with severe and sometimes fatal side effects, HyBryte has been well tolerated and shows no evidence of safety concerns to date. Its mechanism of action is not linked to DNA damage, a significant distinction that positions it as a potentially safer alternative in a treatment landscape where many options carry risks such as melanoma, other malignancies, severe skin damage and premature skin aging.

This favorable safety profile is especially relevant given that all currently available CTCL therapies are only approved following the failure of other treatments, and none have been approved for front-line use. In this context, safety becomes a decisive factor in selecting a treatment course, particularly for older adults who are often managing multiple health conditions. HyBryte’s minimal systemic absorption, non-mutagenic compound and use of a non-carcinogenic visible light source make it uniquely positioned as a safe and effective treatment option. As the CTCL community awaits a first-line therapy, HyBryte stands out as a promising candidate capable of meeting both efficacy and safety demands.

In addition to its strong clinical profile, HyBryte represents a significant commercial opportunity in an area of high unmet medical need. With an estimated global CTCL market potential exceeding $990 million, the therapy is well positioned to address a meaningful segment of the CTCL population. As development advances, HyBryte offers the potential not only to improve patient outcomes but also to establish itself as a valuable new standard in CTCL treatment.

In an era where precision medicine and urgent unmet needs converge, several pharmaceutical leaders are stepping up with bold new advances in cancer and complex disease treatment, from improving survival outcomes in prostate and lung cancer to advancing novel therapies for pulmonary hypertension. These developments reflect a broader commitment across the life sciences industry to accelerate innovation and deliver life-extending, quality-of-life-enhancing options for patients with high-need conditions.

Pfizer Inc. is reporting positive topline results from the overall survival (OS) analysis from its phase 3 EMBARK study. The study evaluated XTANDI(R) (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with biochemical recurrence (BCR) at high risk for metastasis. The announcement was made with Astellas Pharma U.S. Inc. XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in nmHSPC with high-risk biochemical recurrence BCR.

Merck & Co Inc. announced that the first patient has been dosed in the IDeate-Prostate01 phase 3 trial. The phase 3 study evaluates the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) with disease progression during or after treatment with an androgen receptor pathway inhibitor. I-DXd is being jointly developed by Merck and Daiichi Sankyo. While localized prostate cancer has a five-year survival rate of more than 90%, survival decreases to 31% in the advanced or metastatic stage, the company noted, reinforcing the need for new approaches to improve outcomes.

Bristol-Myers Squibb Co. has received critical approval from the European Commission (EC) for a key perioperative regimen. The regimen is for neoadjuvant Opdivo(R) (nivolumab) and chemotherapy followed by surgery and adjuvant Opdivo for the treatment of resectable non-small cell lung cancer (NSCLC) at high risk of recurrence in adult patients whose tumors have PD-L1 expression ≥1%. The EU approval is based on results from the CheckMate-77T trial, which showed perioperative Opdivo improved event-free survival compared to neoadjuvant chemotherapy and placebo followed by surgery and adjuvant placebo.

Insmed Inc. announced positive topline results from its randomized, double-blind, placebo-controlled phase 2b study evaluating the efficacy and safety of treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary arterial hypertension (PAH). According to the announcement, the study met primary and all secondary efficacy endpoints. Insmed noted that it plans to immediately engage with the U.S. Food and Drug Administration regarding a phase 3 trial design for PAH. Insmed plans to initiate a phase 3 trial in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) before the end of 2025 and a phase 3 trial in patients with PAH in early 2026.

These announcements spotlight the momentum building across rare-disease research, with these companies contributing key pieces to the larger puzzle of patient-centered medical breakthroughs. As regulatory engagement continues and phase 3 trials advance, the coming years may bring meaningful shifts in standard-of-care therapies, offering hope to patients facing some of the most challenging diagnoses in medicine today.

For more information, visit Soligenix Inc.

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness.

NNW is where breaking news, insightful content and actionable information converge.

For more information, please visit www.NetworkNewsWire.com

Please view full terms of use and disclaimers on the NNW website applicable to all content provided by NNW, wherever published or re-published: http://www.nnw.fm/Disclaimer

NetworkNewsWire is powered by IBN

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Logo – https://mma.prnewswire.com/media/2660018/5442458/NetworkNewsWire_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/late-stage-pipeline-wins-boost-investor-confidence-in-high-growth-therapeutic-areas-302519950.html

SOURCE NetworkNewsWire

SANTA FE, N.M.
, Aug. 4, 2025 /PRNewswire/ — GreenPower Motor Company Inc. (Nasdaq: GP) (TSXV: GPV) (“GreenPower”), a leading manufacturer and distributor of all-electric, purpose-built, zero-emission medium and heavy-duty vehicles serving the cargo and delivery market, shuttle and transit space and school bus sector, today announced it has signed a contract with the state of New Mexico to implement an all-electric school bus pilot project. The contract is the result of an award made by the state under an RFP published in May.

The two-year pilot project will deploy three GreenPower Type A all-electric, purpose-built, zero-emission Nano BEAST Access school buses in the first school year (2025-26), and three GreenPower Type D all-electric, purpose-built, zero-emission BEAST and Mega BEAST school buses in the second school year (2026-27). The school buses will rotate around the state in five pilot rounds each school year with each round lasting six weeks. GreenPower will install charging systems, provide training for the drivers, mechanics and the community’s first responder and help ensure a seamless testing period.

The contract between GreenPower and the state of New Mexico provides more than $5 million for the purchase of vehicles, cost of charging infrastructure and overall management of the pilot. GreenPower will support the implementation of the project from a location to be established in New Mexico. Based on voluntary requests to participate, school districts are currently being selected by the state to participate in the pilot. The manufacturing of the three Nano BEAST Access school buses is substantially complete and they will be ready for deployment for Round 1 the week of September 15.

“The New Mexico pilot project provides an opportunity to expand the reach of GreenPower’s zero-emission school bus product and gives parents, kids and school districts in the state the opportunity to evaluate the transition to all-electric, purpose-built school buses,” said GreenPower President Brendan Riley. “The project is leveraging the successful pilot that GreenPower conducted in West Virginia, but also has a concentration on evaluating charging options and infrastructure.”

The pilot will include both Level 3 DC fast chargers and Level 2 slow chargers for the Nano BEAST Access school buses, and will evaluate Level 3 DC fast charging in the second year with the BEAST school buses. A part of the second year will be a vehicle-to-grid (V2G) evaluation using the GreenPower Mega BEAST. The Mega BEAST is a 40-foot Type D all-electric, purpose-built, zero-emission school bus that delivers a class-leading range of up to 300 miles on a single charge because of its massive 387 kWh battery pack. The range of the Mega BEAST is greater than any electric school bus in its class. It has more uphill climbing power and the most compelling and cost effective V2G capability for a more stable electric grid and community sustainability in areas where it is deployed.

“We are particularly interested in evaluating charging as a part of the pilot project,” said Mark Roper, Director of the Economic Development Division within the New Mexico Economic Development Department. “Range, charging rates and grid resiliency are critical components of switching to all-electric, zero-emission vehicles.”

GreenPower is partnering with Highland Electric Fleets to install and implement the charging infrastructure necessary for the pilot. In a letter to the state, Highland’s Chief Commercial Officer Brian Buccella shared the company’s commitment to supporting GreenPower in assessing charging infrastructure and creating a reliable EV pilot project in New Mexico. “Our experience delivering and operating electric school buses at scale positions us well to assist in the successful execution of this pilot program. This initiative presents an opportunity to reduce transportation-related emissions in New Mexico communities, protect student health and modernize school transportation,” Buccella said.

For further information contact:

Brendan Riley, President
510) 910-3377

Fraser Atkinson, CEO
(604) 220-8048

Mark Nestlen, Business Development & Strategy
(405) 850-9571

About GreenPower Motor Company Inc.

GreenPower designs, builds and distributes a full suite of high-floor and low-floor all-electric medium and heavy-duty vehicles, including transit buses, school buses, shuttles, cargo van and a cab and chassis. GreenPower employs a clean-sheet design to manufacture all-electric vehicles that are purpose built to be battery powered with zero emissions while integrating global suppliers for key components. This OEM platform allows GreenPower to meet the specifications of various operators while providing standard parts for ease of maintenance and accessibility for warranty requirements. GreenPower was founded in Vancouver, Canada with primary operational facilities in southern California. Listed on the Toronto exchange since November 2015, GreenPower completed its U.S. IPO and NASDAQ listing in August 2020. For further information go to www.greenpowermotor.com

Forward-Looking Statements

This document contains forward-looking statements relating to, among other things, GreenPower’s business and operations and the environment in which it operates, which are based on GreenPower’s operations, estimates, forecasts and projections. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “upon”, “may”, “should”, “will”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. A number of important factors including those set forth in other public filings (filed under the Company’s profile on www.sedar.com) could cause actual outcomes and results to differ materially from those expressed in these forward-looking statements. Consequently, readers should not place any undue reliance on such forward-looking statements. In addition, these forward-looking statements relate to the date on which they are made. GreenPower disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. All amounts in U.S. dollars. ©2025 GreenPower Motor Company Inc. All rights reserved.

View original content to download multimedia:https://www.prnewswire.com/news-releases/greenpower-signs-contract-for-more-than-5-million-with-state-of-new-mexico-for-all-electric-school-bus-pilot-program-302520454.html

SOURCE GreenPower Motor Company

PLEASANTON, Calif.
, Aug. 4, 2025 /PRNewswire/ — Workday, Inc. (NASDAQ: WDAY), the AI platform for managing people, money, and agents, today announced that it will host its financial analyst day on Tuesday, September 16, 2025 in San Francisco at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. The event will take place during Workday Rising, the company’s annual flagship conference for finance, HR, and IT professionals.

A live webcast of the event will be available on the Workday Investor Relations site. The replay of the webcast will be available for a minimum of 180 days after the conference call.

About Workday


Workday
 is the AI platform for managing people, money, and agents. The Workday platform is built with AI at the core to help customers elevate people, supercharge work, and move their business forever forward. Workday is used by more than 11,000 organizations around the world and across industries – from medium-sized businesses to more than 60% of the Fortune 500. For more information about Workday, visit workday.com.

© 2025 Workday, Inc. All rights reserved. Workday and the Workday logo are registered trademarks of Workday, Inc. All other brand and product names are trademarks or registered trademarks of their respective holders.

View original content to download multimedia:https://www.prnewswire.com/news-releases/workday-to-hold-annual-financial-analyst-day-on-september-16-2025-302520432.html

SOURCE Workday Inc.

NetworkNewsWire Editorial Coverage

NEW YORK
, Aug. 4, 2025 /PRNewswire/ — The hospitality industry is undergoing a major transformation powered by artificial intelligence (AI) and robotics, with hotels using automation reporting 30–40% reductions in operational costs, improved guest experiences and better revenue management. The AI in hospitality market size is expected to see exponential growth to $1.46 billion in 2029 at a compound annual growth rate (CAGR) of 57.8% while the global hospitality robotics market is projected to grow from $24.38 billion this year to $107.24 billion in 2034. Leading this shift is Nightfood Holdings Inc. (OTCQB: NGTF) (Profile), a pioneer hospitality entity that combines hotel ownership with AI-driven Robotics-as-a-Service (RaaS) The company recently announced plans to acquire a 155-room Holiday Inn in Victorville, California, its first model property integrating guest-facing robots such as food-delivery concierges and laundry assistants, a proprietary system provided by SGTF subsidiary Skytech. Nightfood has also established a strategic partnership with Bear Robotics to scale automation across its portfolio, which includes an estimated $80 million in assets. Nightfood joins a growing number of leading companies, including Tesla Inc. (NASDAQ: TSLA), SoFi Technologies Inc. (NASDAQ: SOFI), NVIDIA Corp. (NASDAQ: NVDA) and UiPath Inc. (NYSE: PATH), that are leveraging groundbreaking AI and robotics to innovate in their respective industries.

• Nightfood Holdings is
  a pioneer hospitality entity that
  combines hotel ownership with AI-driven Robotics-as-a-Service (RaaS).
• The company is strategically assembling an $80 million portfolio of institutional-grade hotels through targeted acquisitions.
• NGTF is executing a dual-revenue strategy that pairs recurring RaaS income with long-term real estate value creation. 
• Nightfood Holdings is capitalizing on a first-mover advantage by integrating robotics and AI into hotel operations at a foundational level.
• With a seasoned team of executives who have developed more than 50 hotels and managed more than 130 hospitality assets, Nightfood Holdings brings deep industry expertise to every aspect of its growth strategy.

Click here to view the custom infographic of the Nightfood Holdings editorial.

AI, Robotics Revolutionizing Hospitality

Business Research reports that “AI is transforming the hotel industry by optimizing revenue management, personalizing guest experiences, enhancing cybersecurity, and automating operations.” The report notes that future AI in the hotel industry, which includes AI-driven sustainability, biometric check-ins, metaverse hotel previews and more, will lead to compound annual growth rate (CAGR) of more than 50% in the space in the coming years.

Market Research Futures projects that the hospitality robot market will experience a CAGR of more than 71% through 2034 with robotics in hospitality seeing rising levels of trust, acceptance and understanding. “Guests are increasingly demanding personalized experiences when they travel,” the report states. “They want to be able to tailor their stay to their own needs and preferences. Hospitality robots can help to provide personalized guest experiences by offering a variety of services, such as personalized recommendations for restaurants, activities, and attractions; real-time information about hotel amenities and services; the ability to control their room temperature, lighting and other settings. By providing personalized guest experiences, hospitality robots can help to increase guest satisfaction and loyalty.”

These impressive trajectories reflect widespread adoption across hotels, resorts, restaurants and cruise operations seeking cost savings, enhanced service and recovery from staffing shortages. Smart companies such as Nightfood Holdings are capitalizing on these trends, leveraging their expertise and resources to become leaders in the hospitality transformation.

A Bold Real Estate Vision

Nightfood Holdings is strategically assembling an $80 million property portfolio through targeted acquisitions, creating a scalable foundation for its next-generation hospitality platform. By acquiring high-visibility, branded properties in key growth markets, the company is focused on creating a strategic collection of real estate and leading the way in operational innovation. This focused expansion not only builds asset value but also allows for consistent delivery of elevated guest experiences and operating efficiency.

Nightfood just announced that it is “on track to finalize due diligence and enter definitive agreements for the acquisition of two flagship hotel properties in Victorville and Rancho Mirage, California. Combined, these transactions represent approximately $80 million in institutional-grade real estate assets and serve as a cornerstone of the company’s vertically integrated hospitality and automation strategy.”

The 155-room Victorville property is currently a Holiday Inn. Nightfood earlier signed a letter of intent to purchase the property for approximately $41 million, with plans to convert it into a Courtyard by Marriott. The hotel will serve as a flagship property in the company’s portfolio, showcasing operational enhancements and property upgrades intended to boost revenue and brand recognition. Victorville’s strategic location, along one of the busiest transportation corridors between Los Angeles and Las Vegas, positions the property for strong occupancy and long-term performance.

Building on that momentum, Nightfood signed a second letter of intent to acquire a Hilton Garden Inn in Rancho Mirage, California, for roughly $37 million. The property sits adjacent to Disney’s highly anticipated Cotino residential and resort development, a location expected to benefit from substantial traffic and tourism in the coming years. By investing in a branded, upscale asset in such a premium corridor, Nightfood is enhancing both the value and visibility of its growing portfolio.

According to the company, both properties will be integrated into Nightfood’s AI automation platform, serving as operational environments for robotic deployments, data collection and revenue optimization. Together, these acquisitions demonstrate the company’s focus on institutional-quality assets with strong brand affiliations and location advantages. Each addition to the portfolio is carefully selected to support scalability, ensure stable cash flow and serve as a platform for long-term growth. As Nightfood continues to expand its holdings, it is creating a strong and differentiated position in the hospitality real estate space, anchored by quality, operational excellence and future-ready infrastructure.

Recurring Revenue Meets Scalable Property Value

Nightfood Holdings is executing a dual-revenue strategy that pairs recurring RaaS income with long-term real estate value creation. At the core of this approach is the deployment of AI-powered service robots that automate essential hospitality functions, such as food and amenity delivery, linen transport and cleaning, across the company’s hotel properties. These robotic systems are offered on a subscription basis, creating a predictable and scalable revenue stream that is not tied to seasonal occupancy or nightly rates.

Through its Skytech Automated Solutions division, Nightfood is developing and installing robots specifically engineered for the hospitality sector. These include concierge robots that interact directly with guests, autonomous carts that transport laundry and supplies, and cleaning bots that operate efficiently in common areas. By reducing labor demands and increasing operational efficiency, RaaS technology enables hotels to streamline staffing, cut costs and improve the guest experience, all while generating monthly recurring revenue.

This recurring revenue model is being embedded into properties the company is acquiring, including its planned flagship hotels in Victorville and Rancho Mirage, California. These hotels will serve as model sites where the RaaS platform can be refined and demonstrated at scale. The ultimate goal is to license and deploy Nightfood’s robotic systems across a broader network of third-party hotel operators, enabling expansion of the RaaS model beyond company-owned properties.

By combining high-impact automation with direct ownership of real estate assets, Nightfood is creating a vertically integrated business model. The RaaS component delivers consistent, technology-driven revenue, while hotel ownership provides asset appreciation and brand equity. This synergy positions the company to benefit from both short-term income and long-term value creation in a transforming hospitality landscape.

Pioneering the Future of Tech-Enabled Hospitality

Nightfood Holdings is capitalizing on a first-mover advantage by integrating robotics and AI into hotel operations at a foundational level. Through its proprietary RaaS platform, the company is deploying guest-facing and back-of-house service robots that perform tasks such as food and linen delivery, cleaning and concierge support.

These robotic systems are not add-ons but core operational components, designed to streamline workflows, reduce labor costs and enhance the overall guest experience. By owning and operating its initial properties, Nightfood can rapidly prototype and refine its automation technologies in live environments before offering them to third-party operators.

This vertically integrated strategy allows for the seamless fusion of real estate operations with tech deployment, creating a hospitality model that is both operationally efficient and easily scalable. Unlike traditional hotel-management companies or pure-play robotics firms, Nightfood is positioned to generate recurring revenue from automation while also benefiting from asset value appreciation. With pilot programs underway and a growing ecosystem of robotics, AI and strategic partnerships, the company is laying the groundwork for broad market adoption, setting a new standard for how hotels operate in the AI era.

Experienced Leadership Driving Strategic Growth

With a seasoned team of executives who have developed more than 50 hotels and managed more than 130 hospitality assets, Nightfood Holdings brings deep industry expertise to every aspect of its growth strategy. The leadership team combines decades of experience in hotel operations, finance and real estate development, enabling the company to identify high-potential properties, negotiate favorable deal terms and execute value-enhancing improvements with precision.

This hands-on knowledge ensures that acquisitions are not only strategic but also aligned with long-term growth and operational efficiency. The company’s strong operational background also facilitates effective integration of new properties into the portfolio while maintaining high standards of service and performance.

Nightfood’s disciplined approach to capital allocation underpins its ability to scale without overextending. Each acquisition is selected based on rigorous financial modeling, brand potential, and operational upside. By targeting institutional-grade assets in markets with long-term demand drivers, Nightfood ensures both stability and room for innovation. This measured approach minimizes risk while maximizing value creation, allowing the company to balance growth ambitions with sustainable financial management. Paired with its focus on technology integration and recurring revenue through automation, the company’s leadership is executing a clear, focused strategy that balances growth with financial prudence and positions it well for long-term success.

Shaping the Future with AI, Robotics

In addition to Nightfood’s innovation, recent announcements from top-tier tech companies highlight a pivotal moment in the evolution of AI and robotics. As these industry innovators integrate advanced AI systems into their offerings, they are not only enhancing performance and efficiency but also establishing themselves at the forefront of a rapidly evolving global market.

Tesla Inc. announced its most recent developments in AI and robotics during its Q2 2025 earnings report. “Q2 2025 was a seminal point in Tesla’s history: the beginning of our transition from leading the electric vehicle and renewable energy industries to also becoming a leader in AI, robotics and related services,” the report stated. “Our first Robotaxi service launched in Austin in June. While the service is limited in scope, we believe our approach to autonomy, a camera-only architecture with neural networks trained on data from our global fleet of millions of vehicles, allows us to continually improve safety, rapidly scale the network and improve profitability.”

SoFi Technologies Inc. announced that it expanded access to alternative investments funds to provide investors with exposure to multiple private companies that include AI. The company is leveling the financial playing field by offering investment minimums starting at $10. The announcement noted that SoFi has partnered with Templum to give members access to privately held companies via the Cosmos Fund, with asset classes offering sole exposure to top tech companies including SpaceX, Databricks and xAI.

NVIDIA Corp. has released NVIDIA Isaac GR00T N1.5, the first update to the company’s open, generalized, fully customizable foundation model for humanoid reasoning and skills; NVIDIA Isaac GR00T-Dreams, a blueprint for generating synthetic motion data; and NVIDIA Blackwell systems to accelerate humanoid robot development. “Physical AI and robotics will bring about the next industrial revolution,” said Jensen Huang, founder and CEO of NVIDIA. “From AI brains for robots to simulated worlds to practice in or AI supercomputers for training foundation models, NVIDIA provides building blocks for every stage of the robotics development journey.”

UiPath Inc. has been recognized as a leader in the 2025 Gartner(R) Magic Quadrant(TM) for Robotic Process Automation. This marks the seventh consecutive year UiPath has earned this distinction, with the company being positioned highest for its ability to execute. Gartner’s evaluation highlighted UiPath’s leadership in agentic automation, where intelligent software agents can perceive, reason and act autonomously to achieve complex business objectives. This recognition underscores UiPath’s ongoing commitment to advancing AI-driven automation solutions. 

Together, these companies reflect the breadth and impact of AI integration across sectors. As the AI and robotics revolution continues to unfold, these advancements signal a profound transformation in how we live, work and invest.

For more information, visit Nightfood Holdings (NGTF).

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness.

NNW is where breaking news, insightful content and actionable information converge.

For more information, please visit www.NetworkNewsWire.com

Please view full terms of use and disclaimers on the NNW website applicable to all content provided by NNW, wherever published or re-published: http://www.nnw.fm/Disclaimer

NetworkNewsWire is powered by IBN

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements. 

NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Logo – https://mma.prnewswire.com/media/2660018/5442455/NetworkNewsWire_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/hospitality-gets-high-tech-the-future-of-hotel-investment-is-ai-automation-302519916.html

SOURCE NetworkNewsWire

HAYWARD, Calif.
, Aug. 4, 2025 /PRNewswire/ — Ultra Clean Holdings, Inc. (Nasdaq: UCTT), today announced its participation at two upcoming virtual investor conferences:

August 13, 2025: Oppenheimer Annual Virtual 1X1 Technology Conference

August 20, 2025:  Needham 6th Annual Virtual Semiconductor & SemiCap 1×1 Conference

UCT will host one-on-one meetings only.

About Ultra Clean Holdings, Inc.

Ultra Clean Holdings, Inc. is a leading developer and supplier of critical subsystems, components, parts, and ultra-high purity cleaning and analytical services primarily for the semiconductor industry. Under its Products division, UCT offers its customers an integrated outsourced solution for major subassemblies, improved design-to-delivery cycle times, design for manufacturability, prototyping, and high-precision manufacturing. Under its Services Division, UCT offers its customers tool chamber parts cleaning and coating, as well as micro-contamination analytical services. Ultra Clean is headquartered in Hayward, California. Additional information is available at www.uct.com.

Contact:

Rhonda Bennetto

SVP Investor Relations
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/ultra-clean-announces-participation-at-upcoming-investor-conferences-302519911.html

SOURCE Ultra Clean Holdings, Inc.

Company Achieves Multiple Clinical Development Milestones in 2025

Patient Treatment Continues in Two Lung Cancer Clinical Trials

AUSTIN, Texas
, Aug. 4, 2025 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has issued a stockholder letter and corporate update summarizing the Company’s recent achievements across its oncology and diabetes programs and outlines key milestones for 2025 and beyond.

“Genprex has made significant progress across our technology programs this past year, and I am enthusiastic about Genprex’s future as we continue to advance our clinical development program while maintaining streamlined, focused strategies that are important to build value across the entire company,” said Ryan Confer, President and Chief Executive Officer. “We remain dedicated to transforming lives of patients battling cancer and diabetes through our novel gene therapies, and we look forward to executing on a number of upcoming milestones in the second half of 2025 and beyond.”

To read the stockholder letter in its entirety, a digital copy of the Company’s stockholder letter can be found on the Company’s website here.

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company’s lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex’s lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex’s SCLC program has received an FDA Orphan Drug Designation. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In a similar approach for Type 2 diabetes, where autoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K for the year ended December 31, 2024.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex’s ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex’s clinical trials, its intended regulatory submissions and any resulting regulatory approvals; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex’s future growth and financial status, including Genprex’s ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex’s commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; Genprex’s intellectual property and licenses; and Genprex’s current expectations, estimates, forecasts and projections about the industry and markets in which it operates.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations

[email protected]

GNPX Media Contact

Kalyn Dabbs

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-issues-stockholder-letter-and-provides-2025-corporate-update-302519361.html

SOURCE Genprex, Inc.